Literature DB >> 18937058

Movement of heparins across rat gastric mucosa is dependent on molecular weight and pH.

Bita Moazed1, Linda M Hiebert.   

Abstract

PURPOSE: Movement of unfractionated (UFH) and low molecular weight heparins (LMWHs) through gastric mucosa was compared to determine effect of molecular weight on absorption.
METHODS: Rat gastric mucosa, mounted in an Ussing chamber, was bathed in oxygenated Kreb's buffer, containing mannitol on the mucosal (lumen) at pH 7.4 or 4, and glucose on the serosal side (circulation) at pH 7.4. Heparins (10 mg/ml) were added to the mucosal side. Potential difference (PD), resistance, and short circuit current (Isc), were determined. Buffers and tissues were extracted to measure heparin by gel electrophoresis.
RESULTS: PD increased on heparin addition and following a lag period, that was longer for UFH at pH 7.4 and LMWHs at pH 4.0, returned to baseline. Isc increased slightly for UFH at pH 4.0 but significantly for LMWHs at pH 7.4. More UFH or LMWHs were recovered from serosal buffers at pH 4.0 and pH 7.4 respectively. Results suggest UFH and LMWHs cross gastric mucosa faster, and active transport is involved, at pH 4.0 and pH 7.4, respectively.
CONCLUSIONS: Decreasing heparin size, increases movement through gastric mucosa at mucosal buffer pH 7.4 but not pH 4.0. The stomach environment may favor UFH absorption while the intestine environment favors LMWH absorption.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18937058     DOI: 10.1007/s11095-008-9751-8

Source DB:  PubMed          Journal:  Pharm Res        ISSN: 0724-8741            Impact factor:   4.200


  26 in total

1.  Gastro-intestinal absorption of heparin and synthetic heparinoids.

Authors:  E WINDSOR; G E CRONHEIM
Journal:  Nature       Date:  1961-04-15       Impact factor: 49.962

2.  Investigations on plasma activity of low molecular weight heparin after intravenous and oral administrations.

Authors:  M Dryjski; D E Schneider; P Mojaverian; B S Kuo; T D Bjornsson
Journal:  Br J Clin Pharmacol       Date:  1989-08       Impact factor: 4.335

3.  Antithrombotic efficacy in a rat model of the low molecular weight heparin, reviparin sodium, administered by the oral route.

Authors:  L M Hiebert; S M Wice; T Ping; D Herr; V Laux
Journal:  Thromb Haemost       Date:  2001-01       Impact factor: 5.249

4.  Binding and endocytosis of heparin by human endothelial cells in culture.

Authors:  T Bârzu; P Molho; G Tobelem; M Petitou; J Caen
Journal:  Biochim Biophys Acta       Date:  1985-05-30

Review 5.  Development of oral heparin therapy for prophylaxis and treatment of deep venous thrombosis.

Authors:  S R Money; J W York
Journal:  Cardiovasc Surg       Date:  2001-06

6.  Sodium deoxycholate promotes the absorption of heparin administered orally, probably by acting on gastrointestinal mucosa, in rats.

Authors:  S Guarini; W Ferrari
Journal:  Experientia       Date:  1985-03-15

7.  Orally administered heparins prevent arterial thrombosis in a rat model.

Authors:  Cory Pinel; Sandra M Wice; Linda M Hiebert
Journal:  Thromb Haemost       Date:  2004-05       Impact factor: 5.249

8.  Tissue distribution of [14C]sucrose octasulfate following oral administration to rats.

Authors:  Linda M Hiebert; Sandra M Wice; Tidly Ping; Ronald E Hileman; Tfilay Polat; Robert J Linhardt
Journal:  Pharm Res       Date:  2002-06       Impact factor: 4.200

9.  Structural requirements for duodenal permeability of heparin-diamine complexes.

Authors:  G Zoppetti; I Caramazza; Y Murakami; T Ohno
Journal:  Biochim Biophys Acta       Date:  1992-12-08

10.  Antithrombotic activity of oral unfractionated heparin.

Authors:  L M Hiebert; S M Wice; L B Jaques
Journal:  J Cardiovasc Pharmacol       Date:  1996-07       Impact factor: 3.105

View more
  1 in total

1.  Oral fondaparinux: use of lipid nanocapsules as nanocarriers and in vivo pharmacokinetic study.

Authors:  Alyaa Ramadan; Frederic Lagarce; Anne Tessier-Marteau; Olivier Thomas; Pierre Legras; Laurent Macchi; Patrick Saulnier; Jean Pierre Benoit
Journal:  Int J Nanomedicine       Date:  2011-11-21
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.